Alembic Pharmaceuticals Ltd. - Research Center
533573 APLLTD Group (A) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Mar ' 24 | Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | |
|---|---|---|---|---|---|
| Sales | 5,874.06 | 5,149.00 | 4,996.61 | 5,051.44 | 4,132.55 |
| Operating profit | 998.52 | 664.33 | 1,054.46 | 1,572.23 | 1,202.90 |
| Interest | 54.47 | 49.00 | 16.67 | 12.77 | 25.19 |
| Gross profit | 975.37 | 618.88 | 1,087.77 | 1,569.19 | 1,312.46 |
| EPS (Rs) | 33.91 | 17.64 | 40.39 | 59.80 | 51.43 |
Annual
results in details
| Mar ' 24 | Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | |
|---|---|---|---|---|---|
| Other income | 31.32 | 3.55 | 49.98 | 9.73 | 134.75 |
| Stock adjustment | -52.36 | 72.84 | 18.41 | -157.13 | -176.50 |
| Raw material | 1,403.01 | 1,250.08 | 1,111.75 | 1,175.71 | 978.13 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 1,335.91 | 1,094.82 | 1,028.18 | 948.27 | 806.37 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 2,188.98 | 2,066.93 | 1,783.80 | 1,512.36 | 1,321.65 |
| Provisions made | - | - | - | - | - |
| Depreciation | 271.14 | 272.95 | 179.31 | 152.60 | 135.67 |
| Taxation | 37.75 | -0.80 | 114.45 | 241.20 | 197.39 |
| Net profit / loss | 666.48 | 346.73 | 794.00 | 1,175.39 | 969.40 |
| Extra ordinary item | - | - | - | - | -10.00 |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 39.31 | 39.31 | 39.31 | 39.31 | 37.70 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 17.00 | 12.90 | 21.10 | 31.12 | 29.11 |
| GPM (%) | 16.52 | 12.01 | 21.55 | 31.00 | 30.76 |
| NPM (%) | 11.29 | 6.73 | 15.73 | 23.22 | 22.72 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis